register free | resend password


UCB and Novartis to expand cooperation in Germany

ID: 1003502
recent pressrelease next pressrelease

(Thomson Reuters ONE) - * UCB further strengthens its second largest market, Germany * Strong internal medicine presence enlarged by cardio-metabolic partnering with Novartis * With Dafiro® UCB extends the product line for the treatment of hypertension and enters the fast growing diabetes market with new oral anti-diabetics Jalra® and Icandra®Brussels (Belgium), 24 August 2009 - 7:00 am press release, regulatedinformation - UCB and Novartis announced today that they entered intoa licensing agreement for cardiovascular and diabetes products inGermany. Under the agreement, UCB has extended commercial rights forthe German market to the cardiovascular medication Provas®(valsartan) beyond 2011 and has licensed in commercial rights for twoline extensions: Dafiro® (valsartan and amlodipine) and Dafiro HCT®(valsartan, amlodipine and HCT). Dafiro HCT® is the first drug forthe treatment of hypertension with a combination of three compoundsin about 20 years. In addition, UCB will co-commercialize the two neworal anti-diabetics Jalra® and Icandra® (vildagliptin andvildagliptin + metformin)."With this agreement we are building on our strengths in Germany, ourexcellent position in the Internal Medicine segment," said WillyCnops, Vice President UCB and Managing Director Germany. "We areextending our cardiovascular and metabolic product portfolio with themost attractive and innovative treatment options to date in line withUCB's ambitions to offer the best medicines to our patients."UCB Germany, with a focus on the fields of central nervous system,immunology disorders and internal medicine, is employing about 1 400people (June 2009). In the field of internal medicine in Germany, UCBcovers so far a spectrum of indications ranging from cardiovasculardiseases to respiratory diseases through to vascular diseases.UCB Germany is an affiliate of UCB S.A. Brussels, Belgium.For further informationNancy Nackaerts, External Communications, UCBT +32 (0)473.864.414, nancy.nackaerts(at)ucb.comMichael Tuck-Sherman, Investor Relations, UCBT +32.(0)2.559.9712, michael.tuck-sherman(at)ucb.comNotes to the EditorAbout Provas®Provas® (valsartan) is administered to treat essential hypertension,unstable cardiac insufficiency, and for post-myocardial-infarctiontreatment. Valsartan is a member of the modern class of substancescalled angiotensin II receptor antagonists which, apart frompossessing a high efficacy, also show excellent tolerability.Three dosage sizes are available for treating unstable cardiacinsufficiency and for post-myocardial-infarction treatment (Provas®40mg, Provas® 80 mg and Provas® 160 mg).Provas® comes in eight available dosage sizes for treating essentialhypertension (Provas® 80mg, Provas® 160mg, Provas® 320mg, Provas® 80comp, Provas® 160 comp, Provas® 320 comp, Provas® 160 maxx, andProvas® 320 maxx). Provas® has already proved successful asmonotherapy and, particularly due to a side-effects profile equal toplacebo, exhibits a high level of patient adherence.The fixed combination Provas® 80, 160 and 320 comp and Provas® 160and 320 maxx can - through the synergism of the active principles oftwo substances (valsartan + hydrochlorothiazide) - significantlyincrease the blood pressure reduction efficacy of Provas® asmonotherapy.About Jalra® and Icandra®Jalra® (vildagliption) and Icandra® (vildagliptin plus metformin)contain vildagliptin, an innovative oral antidiabetic compound fromthe class of inhibitors of dipeptidyl-peptidase IV (DPP-4).Inhibition of DPP-4 slowes down the inactivation of Glucagon-likePeptide-1(GLP-1) in the gut, thus promoting the glucose-dependingsynthesis and release of insuline from the pancreas, and inhibitingthe release of glucagon. Metformin is an active compound used in theoral treatment of diabetes mellitus for many years.About Dafiro®Dafiro® contains two compounds - amlodipine and valsartan. Dafiro®is administered to patients suffering from essential hypertension(high blood pressure) whose blood pressure cannot be sufficientlyregulated by taking amlodipine or valsartan alone. Dafiro hencecombines two antihypertensive substances with complementarymechanisms of action: the calcium antagonist amlodipine and theangiotensin II antagonist valsartan. This combination has anadditive antihypertensive effect, lowering blood pressure moreeffectively than each of the components is capable of alone.About UCBUCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical companydedicated to the research, development and commercialization ofinnovative medicines with a focus on the fields of central nervoussystem and immunology disorders. Employing approximately 10 000people in over 40 countries, UCB generated revenue of EUR 3.6 billionin 2008. UCB is listed on Euronext Brussels (symbol: UCB).Forward looking statementThis press release contains forward-looking statements based oncurrent plans, estimates and beliefs of management. Such statementsare subject to risks and uncertainties that may cause actual resultsto be materially different from those that may be implied by suchforward-looking statements contained in this press release. Importantfactors that could result in such differences include: changes ingeneral economic, business and competitive conditions, effects offuture judicial decisions, changes in regulation, exchange ratefluctuations and hiring and retention of its employees.For the pdf-version of this press release, please click on the linkbelow:http://hugin.info/133973/R/1336528/318111.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: hugin
print pressrelease  send to a friend  

Date: 08/24/2009 - 07:01
Language: English
News-ID 1003502
Character count: 0
Kontakt-Informationen:
Firma: UCB
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: London
Telefon:

Comments:



Number of hits: 229

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 432
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 43


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.